Profile
K Harold Fletcher is Secretary, Chief Legal & Strategy Officer at Celularity, Inc. since 2026.
Formerly, Mr. Fletcher was Chief Compliance Officer & Deputy General Counsel at Celularity, Inc. from 2021 to 2022, Senior Corporate Counsel at Kadmon Corp.
LLC from 2015 to 2018, and Associate at Sedgwick LLP from 2012 to 2015.
Education includes undergraduate studies at Rutgers State University of New Jersey and graduate studies at Seton Hall University.
K Fletcher active positions
| Companies | Position | Start |
|---|---|---|
| CELULARITY INC. | General Counsel | 01/01/2026 |
Former positions of K Fletcher
| Companies | Position | End |
|---|---|---|
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | General Counsel | 01/01/2018 |
Sedgwick LLP
Sedgwick LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01/01/2015 |
| CELULARITY INC. | Compliance Officer | 01/07/2022 |
Training of K Fletcher
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seton Hall University
Seton Hall University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sedgwick LLP
Sedgwick LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Celularity, Inc.
Celularity, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that discovers cancer sub-types and therapeutic options for cancer patients | Commercial Services |
- Stock Market
- Insiders
- K Fletcher
















